Melatonin

Melatonin, or N-acetyl-5-methoxytryptamine, is an indolamine hormone primarily produced by the pineal gland and synthesized locally in the retina, following a circadian rhythm with higher levels at night. Researchers primarily study melatonin for its role in regulating sleep and circadian rhythms, as well as its antioxidant and anti-inflammatory properties. Key findings indicate that melatonin acts as a potent antioxidant in the placenta during pregnancy, reducing oxidative stress and inflammation, while also influencing the growth hormone axis in response to exercise. Clinical evidence suggests that melatonin supplementation may improve sleep quality and synchronize circadian rhythms, offering a potential alternative to conventional sleep medications. Current research continues to explore the therapeutic applications of melatonin, particularly in sleep disorders, mood regulation, and its receptor-mediated effects.

Melatonin, also known as N-acetyl-5-methoxytryptamine, is an endogenous hormone primarily produced by the pineal gland in the brain and also synthesized locally in the retina. It belongs to the class of indolamines and is known for its role in regulating circadian rhythms and sleep-wake cycles. In addition to its endogenous production, melatonin is available as a synthetic supplement, commonly used to aid sleep and manage circadian rhythm disorders. Researchers have observed that melatonin serves multiple physiological roles, including acting as an antioxidant and anti-inflammatory agent. It is particularly important during pregnancy, where it is synthesized by the placenta to maintain a stable environment for fetal development. Melatonin also influences the growth hormone/IGF-1 axis, potentially affecting growth hormone levels in conjunction with resistance exercise. The mechanism of action of melatonin involves binding to high-affinity G protein-coupled receptors, MT1 and MT2, which mediate its effects on sleep, mood disorders, and neuroprotection. These receptors are integral to its ability to regulate circadian rhythms and have been the focus of therapeutic research, leading to the development of melatonin receptor agonists. Pharmacokinetically, melatonin has a short half-life and is metabolized primarily in the liver. Its bioavailability is limited due to first-pass metabolism when taken orally. Clinically, melatonin is used for the treatment of sleep disorders, including insomnia and circadian rhythm sleep-wake disorders. It is generally well-tolerated with a favorable safety profile, making it an alternative to traditional sleep medications. Regulatory approval varies by country, with melatonin available over-the-counter in some regions and as a prescription medication in others.

Melatonin acts on MT1 and MT2 receptors, which are G protein-coupled receptors. Activation of these receptors influences the regulation of circadian rhythms and sleep, as well as mood and neuroprotection through downstream signaling pathways that affect neuronal activity and hormone secretion.

Melatonin primarily exerts its effects through the activation of two high-affinity G protein-coupled receptors, MT1 and MT2, which are involved in the modulation of the cAMP/PKA signaling pathway. This receptor activation influences various biological processes, including the regulation of circadian rhythms, sleep onset, and immune homeostasis, particularly during pregnancy where it acts as an antioxidant and anti-inflammatory agent in the placenta. While the overall mechanism is well-characterized, some aspects of melatonin's signaling pathways and their full physiological implications remain to be fully elucidated.

Current evidence is limited regarding the long-term effects of melatonin supplementation on various populations, particularly in pregnant women and the elderly, where its role as an antioxidant and anti-inflammatory agent requires further exploration. Additionally, while the pharmacological properties of melatonin receptors MT1 and MT2 have been studied, there is a need for larger randomized controlled trials to clarify the specific therapeutic effects of selective melatonin receptor agonists in treating mood disorders and sleep-related issues. Further research is needed to investigate the interactions between melatonin and the growth hormone/IGF-1 axis in diverse demographics, as well as the potential implications of melatonin on metabolic health and its safety profile in long-term use.